CYTH vs. DYAI, OKYO, SABS, ESLA, QNCX, NKGN, SRZN, INKT, TARA, and INAB
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Dyadic International (DYAI), OKYO Pharma (OKYO), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), Quince Therapeutics (QNCX), NKGen Biotech (NKGN), Surrozen (SRZN), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry.
Cyclo Therapeutics (NASDAQ:CYTH) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.
Cyclo Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
In the previous week, Cyclo Therapeutics had 3 more articles in the media than Dyadic International. MarketBeat recorded 6 mentions for Cyclo Therapeutics and 3 mentions for Dyadic International. Cyclo Therapeutics' average media sentiment score of 0.49 beat Dyadic International's score of 0.00 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
Dyadic International has a net margin of -234.39% compared to Cyclo Therapeutics' net margin of -1,864.03%. Dyadic International's return on equity of -81.57% beat Cyclo Therapeutics' return on equity.
Dyadic International received 151 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Cyclo Therapeutics an outperform vote while only 63.97% of users gave Dyadic International an outperform vote.
68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by insiders. Comparatively, 28.8% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Dyadic International has higher revenue and earnings than Cyclo Therapeutics. Dyadic International is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cyclo Therapeutics presently has a consensus price target of $3.20, suggesting a potential upside of 113.33%. Dyadic International has a consensus price target of $6.00, suggesting a potential upside of 319.58%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Cyclo Therapeutics.
Summary
Dyadic International beats Cyclo Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
